Recent Price Movement and Market Context
On 17 Mar 2026, Vivimed Labs Ltd’s share price declined by 2.27% to reach Rs.6.45, the lowest level recorded in the past year. This drop extends a four-day losing streak during which the stock has fallen by 9.15%. The stock’s performance today lagged its sector by 2.86%, indicating relative weakness compared to peers. Furthermore, Vivimed Labs is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a sustained downtrend in technical terms.
In contrast, the broader market has shown resilience. The Sensex opened 323.83 points higher and was trading at 75,836.56, up 0.44% at the time of reporting. However, the Sensex itself is trading below its 50-day moving average, with the 50 DMA positioned below the 200 DMA, suggesting some underlying caution in the market. Mega-cap stocks have been leading the gains, while micro-cap stocks like Vivimed Labs have struggled to keep pace.
Over the past year, Vivimed Labs has delivered a flat return of 0.00%, significantly underperforming the Sensex’s 2.06% gain. The stock’s 52-week high was Rs.23.94, highlighting the extent of the decline from its peak.
Built for the long haul! Consecutive quarters of strong growth landed this Small Cap from Chemicals on our Reliable Performers list. Sustainable gains are clearly ahead!
- - Long-term growth stock
- - Multi-quarter performance
- - Sustainable gains ahead
Financial Performance and Fundamental Concerns
Vivimed Labs’ financial health remains a key concern. The company has not declared any financial results in the last six months, contributing to uncertainty around its current performance. Its long-term fundamental strength is rated weak, as reflected in its recent downgrade from a Sell to a Strong Sell rating on 5 Feb 2026, with a Mojo Score of 17.0.
The company’s ability to service its debt is limited, with a high Debt to EBITDA ratio of 12.57 times. This elevated leverage ratio indicates significant financial risk and pressure on cash flows. Additionally, the average Return on Equity (ROE) stands at a modest 1.75%, signalling low profitability generated from shareholders’ funds.
Profitability has deteriorated sharply over the past year, with profits falling by 386%. The flat results reported in December 2025 further underscore the lack of growth momentum. These factors collectively contribute to the stock’s classification as risky relative to its historical valuation levels.
Shareholding Pattern and Market Risk
The majority of Vivimed Labs’ shares are held by non-institutional investors, which may affect liquidity and trading dynamics. The micro-cap status of the company also adds to the volatility and risk profile of the stock.
Technical Indicators Overview
Technical analysis presents a mixed but predominantly cautious picture. On a weekly basis, the MACD, RSI, and Bollinger Bands all indicate bearish trends, while monthly indicators show mild bearishness or no clear trend. The daily moving averages suggest a mildly bullish stance, but this is overshadowed by the broader weekly and monthly bearish signals.
The KST indicator is mildly bearish weekly but mildly bullish monthly, and Dow Theory analysis shows no clear weekly trend with a mildly bearish monthly outlook. On-balance volume (OBV) indicates no significant trend on either weekly or monthly timeframes.
Is Vivimed Labs Ltd your best bet? SwitchER suggests better alternatives across peers, market caps, and sectors. Discover stocks that could deliver more for your portfolio!
- - Better alternatives suggested
- - Cross-sector comparison
- - Portfolio optimization tool
Summary of Key Metrics
To summarise, Vivimed Labs Ltd’s stock has declined to Rs.6.45, its lowest level in 52 weeks, reflecting a combination of weak financial results, high leverage, and subdued profitability. The stock’s performance over the past year has been flat, with significant profit erosion and a downgrade in its Mojo Grade to Strong Sell. Technical indicators predominantly signal bearish momentum, and the stock trades below all major moving averages.
While the broader market and mega-cap stocks have shown some resilience, Vivimed Labs remains under pressure as a micro-cap stock with a challenging financial profile. The majority non-institutional shareholding and elevated risk metrics further contribute to the cautious outlook surrounding the stock.
Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →
